| 钱玥.抗肝癌合剂对荷肝癌H22小鼠肿瘤细胞周期的影响[J].浙江中西医结合杂志,2016,26(6): |
| 抗肝癌合剂对荷肝癌H22小鼠肿瘤细胞周期的影响 |
| Effect of MAALC on the mitotic cycle situation of the Mouse H22 Model’s tumor. |
| 投稿时间：2016-01-18 修订日期：2016-04-11 |
| DOI： |
| 中文关键词: 抗肝癌合剂，肝癌，昆明小鼠，细胞周期 |
| 英文关键词:MAALC , Liver Cancer, KM Mouse,Mitotic cycle |
| 基金项目:抗肝癌合剂治疗原发性肝癌的临床观察及基础研究 |
|
| 摘要点击次数: 719 |
| 全文下载次数: 1 |
| 中文摘要: |
| 目的 观察抗肝癌合剂对荷肝癌H22小鼠移植瘤的生长情况及肿瘤细胞周期分布。方法 将H22腹水型瘤细胞悬液接种至昆明小鼠右腋窝皮下，分组灌胃给药。10天后，小鼠剥离移植瘤，称取瘤重，计算抑瘤率，流式细胞仪检测分析细胞周期情况，计算细胞增值指数。结果 抗肝癌合剂能明显抑制移植瘤组织的生长，中药低、中、高剂量组及5-Fu组、中药＋5-Fu组的抑瘤率分别为0.64%、15.17%、15.08%、64.86%、66.33%；抗肝癌合剂能使肿瘤组织细胞阻滞于G0/G1期，表现为G0/G1期细胞增多，S、G2/M期细胞相应减少，细胞增值指数PI各组均较模型对照组为小，中药低剂量组与模型对照组比较无差异（P>0.05）；其余各组与模型对照组比较均有显著性差异(P<0.01)。结论 抗肝癌合剂对荷肝癌H22小鼠肿瘤的生长有明显的抑制作用，使肿瘤组织细胞阻滞于G0/G1期。 |
| 英文摘要: |
| Objective Observing the effect of MAALC（Melting Agent of Anti-Liver Cancer） on the tumor growth and the mitotic cycle situation of mouse H22 model .Methods KM mice are inoculated the H22 liver carcinoma cell at right armpit, split them into some groups and feed medicine. Ten days later, 60 mice from every group are killed for the purposes of tumor detaching, weight measuring and restraining tumor rates calculation. Then, we analyze mitotic cycle situation of the tumor cell, and calculate the cell increment index.Results MAALC can restrain the growth of tumor obviously. The rates of restraining tumor of MAALC groups (low, normal and high dose groups), 5-FU group and MAALC+5-FU group are 0.64%、15.17%、15.08%、64.86%、66.33%；The MAALC hinders the tumor cell in the G0/G1 times. The performance is the increase of G0/G1 times cell, the reduction of S and G2/M times cell correspondingly. All of the groups’proliferous index is less than the model one significantly (P<0.01), except the MAALC low dose one(P>0.05).Conclusion MAALC can restrain the growth of tumor obviously, hinder the tumor cell in the G0/G1 times. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
